Effects of combinations of a molsidomin with different antithrombotic drugs in laser-induced thrombosis.
Molsidomin is a vasodilating drug and a specific activator of the endothelium-derived relaxing factor (EDRF). Molsidomin has been found to prevent thrombus formation in various animal thrombosis models. To obtain more information about a possible interaction of Molsidomin with other vasoactive agents, Molsidomin, Iloprost, HN-11500, Fraxiparin and Aspisol have been investigated alone and in combinations. The antithrombotic effect of these agents was studied in a thrombosis model in rats, in which mesenteric venules, with a diameter of 20-30 microns, were injured by Argon laser produced lesions. In this animal microcirculatory thrombosis model all agents showed a significant dose dependent antithrombotic effect. A strong additive effect was observed when Molsidomin was infused together with Iloprost. An additive effect was also observed when Molsidomin was administered with Fraxiparin. There was a slight but non significant effect between Molsidomin and the thromboxane receptor antagonist. No additive effect was shown when a minimal effective dose of Molsidomin was infused together with a minimal effective dose of Aspisol.
Giedrojć
J
J
Department of Haematology, Medical School, Białystok, Poland.
Bielawiec
M
M
Jaromin
J
J
Breddin
H K
HK
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D007834:Lasers; D008297:Male; D008981:Molsidomine / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000209:etiology
D005343:Fibrinolytic Agents; D008981:Molsidomine